ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Total Current Assets : HK$926.67 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. ImmuneOnco Biopharmaceuticals (Shanghai)'s total current assets for the quarter that ended in Dec. 2024 was HK$926.67 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Assets Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Assets Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Total Current Assets

862.15

727.95

751.10

926.67

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Current Assets	Get a 7-Day Free Trial			727.95	599.42	751.10	627.19	926.67

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	803.02	+	0.196	+	0	+	123.457
	=	926.67

ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	803.02	+	0.196	+	0	+	123.457
	=	926.67

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

ImmuneOnco Biopharmaceuticals (Shanghai)'s Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	803.02	-	260.182	+	0.75 * 0.017	+	0.5 * 0
=	542.85

ImmuneOnco Biopharmaceuticals (Shanghai) Total Current Assets Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

R9Z:Germany

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Tian Wenzhi	2501 Other
Yu Xiaoyong	2201 Interest of corporation controlled by you
Shang Hai Zhang Ke Ling Yi Sheng Fan Chuang Ye Tou Zi Zhong Xin You Xian He Huo	2101 Beneficial owner
Shang Hai Zhang Jiang Ke Ji Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Lav Immon Hong Kong Limited	2101 Beneficial owner
Ho Yao
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Gba Fund Investment Limited	2101 Beneficial owner
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines